These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9175618)

  • 1. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat.
    Matto V; Harro J; Allikmets L
    Neuropharmacology; 1997 Mar; 36(3):389-96. PubMed ID: 9175618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of cholecystokinin A and B receptor antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rat.
    Matto V; Harro J; Allikmets L
    J Physiol Pharmacol; 1996 Dec; 47(4):661-9. PubMed ID: 9116333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.
    Chopin P; Briley M
    Psychopharmacology (Berl); 1993; 110(4):409-14. PubMed ID: 7870910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.
    Rataud J; Darche F; Piot O; Stutzmann JM; Böhme GA; Blanchard JC
    Brain Res; 1991 May; 548(1-2):315-7. PubMed ID: 1868342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats.
    Männistö PT; Lang A; Harro J; Peuranen E; Bradwejn J; Vasar E
    Naunyn Schmiedebergs Arch Pharmacol; 1994 May; 349(5):478-84. PubMed ID: 8065461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.
    Bickerdike MJ; Marsden CA; Dourish CT; Fletcher A
    Eur J Pharmacol; 1994 Dec; 271(2-3):403-11. PubMed ID: 7705440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of drugs acting on CCK receptors and rat free exploration in the exploration box.
    Matto V; Harro J; Allikmets L
    J Physiol Pharmacol; 1997 Jun; 48(2):239-51. PubMed ID: 9223028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: evidence for a novel CCK receptor subtype?
    van Kampen J; Stoessl AJ
    Neuropharmacology; 1997; 36(11-12):1679-88. PubMed ID: 9517439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
    Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT
    Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze.
    Kõks S; Soosaar A; Võikar V; Bourin M; Vasar E
    Neuropeptides; 1999 Feb; 33(1):63-9. PubMed ID: 10657473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-exploratory effect of N-methyl-D-aspartate in elevated plus-maze. Involvement of NMDA and CCK receptors.
    Vasar E; Harro J; Lang A; Soosaar A; Oöpik T; Kôks S; Sihver S; Volke V
    Eur Neuropsychopharmacol; 1993 Mar; 3(1):63-73. PubMed ID: 8471831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
    Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
    Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze.
    Wilson J; Watson WP; Little HJ
    Psychopharmacology (Berl); 1998 May; 137(2):120-31. PubMed ID: 9629998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation.
    Varty GB; Morgan CA; Cohen-Williams ME; Coffin VL; Carey GJ
    Neuropsychopharmacology; 2002 Sep; 27(3):357-70. PubMed ID: 12225693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.
    Revel L; Mennuni L; Garofalo P; Makovec F
    Behav Pharmacol; 1998 May; 9(3):183-94. PubMed ID: 9832933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.
    Dawson GR; Rupniak NM; Iversen SD; Curnow R; Tye S; Stanhope KJ; Tricklebank MD
    Psychopharmacology (Berl); 1995 Sep; 121(1):109-17. PubMed ID: 8539335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.
    Poncelet M; Arnone M; Heaulme M; Gonalons N; Gueudet C; Santucci V; Thurneyssen O; Keane P; Gully D; Le Fur G
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Jul; 348(1):102-7. PubMed ID: 8397341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations.
    Kõks S; Männistö PT; Bourin M; Shlik J; Vasar V; Vasar E
    J Psychiatry Neurosci; 2000 Jan; 25(1):33-42. PubMed ID: 10721682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats.
    Lu L; Zhang B; Liu Z; Zhang Z
    Brain Res; 2002 Nov; 954(1):132-40. PubMed ID: 12393241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.